Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III adjuvant transcriptomic-guided chemotherapy allocation trial in resected pancreatic ductal adenocarcinoma
2020-004906-79Phase 3Active
- Sponsor
- Heidelberg University
- Start
- Jul 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, capecitabine, fluorouracil, irinotecan, folinic acid and 1 more in pancreatic adenocarcinoma (PDAC) and pancreatic acinar cell carcinoma (PACC) (2 arms), sponsored by Heidelberg University. Primary endpoint: Disease-free survival. Started Jul 2021; status: active.
02
Drugs
gemcitabinecapecitabinefluorouracilirinotecanfolinic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic acinar cell carcinoma (PACC)
Beyond the preview
Go deeper on 2020-004906-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004906-79.